Journal article
Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck
World journal of clinical oncology, Vol.6(5), pp.166-173
10/10/2015
DOI: 10.5306/wjco.v6.i5.166
PMCID: PMC4600191
PMID: 26468453
Abstract
AIM: To investigate whether selenomethionine (SLM) reduces mucositis incidence in patients with head and neck squamous cell cancer (HNSCC) undergoing concurrent chemoradiation (CRT).
METHODS: In this multi-institutional, randomized, double-blind phase II trial, patients with Stage III or IV HNSCC received SLM 3600 mu g/m(2) or placebo twice daily for 7 d prior to CRT, once daily during CRT, and daily for 3 wk following CRT. CRT consisted of 70 Gy at 2 Gy per fraction with cisplatin 100 mg/m(2) IV on days 1, 22, and 43.
RESULTS: Eighteen patients were randomized, 10 received SLM, and there were no differences in baseline factors. There was no difference in mucositis or patient-reported side effects between groups. There was no difference in overall or relapse-free survival at 12 mo.
CONCLUSION: Addition of SLM to CRT for HNSCC was well-tolerated but did not lower the incidence of severe mucositis or improve quality of life or survival outcomes.
Details
- Title: Subtitle
- Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck
- Creators
- Michael Mix - Roswell Park Cancer InstituteAnurag K. Singh - Roswell Park Cancer InstituteMichael Tills - Roswell Park Cancer InstituteShiva Dibaj - Roswell Park Cancer InstituteAdrienne Groman - Roswell Park Cancer InstituteWainwright Jaggernauth - Roswell Park Cancer InstituteYoucef Rustum - Roswell Park Cancer InstituteMichael B. Jameson - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- World journal of clinical oncology, Vol.6(5), pp.166-173
- DOI
- 10.5306/wjco.v6.i5.166
- PMID
- 26468453
- PMCID
- PMC4600191
- NLM abbreviation
- World J Clin Oncol
- ISSN
- 2218-4333
- eISSN
- 2218-4333
- Publisher
- Baishideng Publishing Group Inc
- Number of pages
- 8
- Grant note
- P30CA016056 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Health Research Council of New Zealand
- Language
- English
- Date published
- 10/10/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359594502771
Metrics
7 Record Views